Hyper-CVAD方案联合奥法木单抗作为成人费城染色体阴性B细胞急性淋巴细胞白血病一线治疗:单臂2期试验
这项单臂2期试验在MD安德森癌症中心纳入69例新诊断Ph阴性CD20阳性B细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤成人患者,接受Hyper-CVAD联合奥法木单抗治疗。中位随访44个月,4年无事件生存率59%,4年总生存率68%,总缓解率98%。研究者认为该方案安全有效。
要点
- Hyper-CVAD联合奥法木单抗治疗Ph阴性CD20阳性B细胞急性淋巴细胞白血病,4年无事件生存率59%,4年总生存率68%。
- 总缓解率为98%(65例中64例),中位随访44个月。
- 最常见3-4级非血液学不良事件为感染,诱导期65例中35例(54%),巩固期68例中53例(78%)。
核心结论
- Hyper-CVAD联合奥法木单抗在成人Ph阴性CD20阳性B细胞急性淋巴细胞白血病中安全且有效。
- 研究者认为,联合靶向CD19和CD22的新型单克隆及双特异性抗体可能进一步改善结局并降低化疗强度与疗程。
研究设计与样本
- 单臂2期试验,在MD安德森癌症中心(美国德克萨斯州休斯顿)进行。
- 纳入新诊断、Ph阴性、CD20表达至少1%的B细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤成人患者69例(67例白血病,2例淋巴母细胞淋巴瘤;中位年龄41岁,IQR 32-50),其中33例(48%)年龄18-39岁。
- 治疗方案:Hyper-CVAD方案(第1、3、5、7疗程)与高剂量甲氨蝶呤和阿糖胞苷(第2、4、6、8疗程)交替,最多8个疗程;奥法木单抗在第1、3疗程第1、11天及第2、4疗程第1、8天给药,共8剂,首剂300 mg静脉注射,后续剂量2000 mg静脉注射;维持治疗30个疗程(6-巯基嘌呤、长春新碱、甲氨蝶呤、泼尼松),含4个强化疗程(第6-7和第18-19疗程为高剂量甲氨蝶呤联合L-天冬酰胺酶及Hyper-CVAD联合奥法木单抗)。
- 主要终点为无事件生存、总缓解和总生存;所有入组患者纳入主要分析和安全性分析。
- 试验注册号ClinicalTrials.gov NCT01363128;入组时间2011年8月26日至2017年5月18日。
主要发现
- 中位随访44个月(26-53),4年无事件生存率为59%(95%CI 48-73);18-39岁青少年和年轻成人中为69%(95%CI 54-87)。
- 4年总生存率为68%(95%CI 58-81);18-39岁青少年和年轻成人中为74%(95%CI 60-91)。
- 总缓解率为98%(65例中64例)。
- 33例患者中9例(27%)为Ph样急性淋巴细胞白血病。
- 最常见3-4级非血液学不良事件为感染:诱导期65例中35例(54%),巩固期68例中53例(78%)。
临床怎么用
- 原文结论认为Hyper-CVAD联合奥法木单抗在成人Ph阴性CD20阳性B细胞急性淋巴细胞白血病中安全且有效。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia. Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small extracellular loop of CD20 and has greater in vitro complement-mediated cytotoxicity than rituximab. In this study, we assessed the activity and safety of ofatumumab in combination with chemotherapy in patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukaemia. METHODS: This was a single-arm, phase 2 trial done at the MD Anderson Cancer Center (Houston, TX, USA). Patients with newly diagnosed, Ph-negative B-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma with CD20 expression of at least 1% were eligible. Patients were treated with up to eight courses of the hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) on courses 1, 3, 5, and 7 alternating with high-dose methotrexate and cytarabine on courses 2, 4, 6, and 8. Ofatumumab was administered on days 1 and 11 of courses 1 and 3 and on days 1 and 8 of courses 2 and 4 for a total of eight doses. The first dose of ofatumumab was 300 mg intravenously and all subsequent doses were 2000 mg intravenously. Patients received 30 courses of maintenance therapy with 6-mercaptopurine, vincristine, methotrexate, and prednisone (POMP), with four intensification courses (high-dose methotrexate plus L-asparaginase and hyper-CVAD plus ofatumumab on courses 6-7 and 18-19). The primary endpoints were event-free survival, overall response, and overall survival. All enrolled patients were included in the primary and safety analyses. The trial is registered with ClinicalTrials.gov, NCT01363128. FINDINGS: Between Aug 26, 2011, and May 18, 2017, 69 patients (67 patients had B-cell acute lymphoblastic leukaemia and two had B-cell lymphoblastic lymphoma; median age 41 years [IQR 32-50]) were enrolled and treated, including 33 (48%) aged between 18 and 39 years. Nine (27%) of 33 patients had Ph-like acute lymphoblastic leukaemia. With a median follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87) in adolescents and young adults aged 18-39 years. 4-year overall survival was 68% (58-81); 74% (60-91) in adolescents and young adults. The overall response rate was 98% (64 of 65 patients). The most common non-haematological grade 3 or 4 adverse events were infections (35 [54%] of 65 patients during induction and 53 [78%] of 68 patients during consolidation). Ten (14%) of 69 patients died in complete remission from sepsis (two [3%]), cardiac arrest (one [1%]), therapy-related acute myeloid leukaemia (two [3%]), and haematopoietic stem-cell transplantation complications (five [7%]). None of these deaths were considered related to ofatumumab treatment by the study investigators. INTERPRETATION: The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukaemia. Modifications of this regimen with the addition of novel monoclonal and bispecific antibody constructs targeting CD19 and CD22 might further improve outcomes and allow reduction in the intensity and duration of chemotherapy. FUNDING: Novartis.
引用
- Jabbour E, Richard-Carpentier G, Sasaki Y, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020. PMID: 32589978. doi:10.1016/S2352-3026(20)30144-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。